查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1559019

尿失禁治療市場：全球產業分析、規模、佔有率、成長、趨勢，2024-2031年預測

Urinary Incontinence Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 170 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research最近發布了一份關於全球尿失禁治療市場的綜合報告。本報告對關鍵市場動態進行了深入分析，包括市場驅動因素、趨勢、機會和挑戰，並對市場結構提供了深入的見解。

主要見解

  • 尿失禁治療市場規模（2024年）：44億美元
  • 預估市場規模（2031年）：58億美元
  • 全球市場成長率（2024-2031年年複合成長率）：4.1%

尿失禁治療市場：調查範圍

尿失禁治療包括多種目的是控制和緩解尿失禁症狀的治療方法，尿失禁影響世界上很大一部分人口。這些治療包括藥物治療、手術介入和非藥物管理策略。該市場以醫院、診所、泌尿中心和家庭護理機構為目標，提供多種治療選擇，包括抗膽鹼能藥物、β-3 腎上腺素促效劑、手術設備和骨盆底肌肉訓練。

市場促進要因：

全球尿失禁治療市場由幾個關鍵因素推動，包括老齡化人口中尿失禁盛行率的上升以及對可用治療方案的認識不斷提高。治療技術的進步，例如微創手術技術和新型藥物製劑，提高治療效果和患者滿意度。此外，日益採用生活方式改變和行為療法以及醫療保健成本的上升也推動了市場擴張。

市場抑制要因：

雖然尿失禁治療市場有望實現積極成長，但它面臨著治療成本高、保險覆蓋範圍有限以及患者對各種治療反應不同等挑戰。先進外科手術和長期藥物治療的高成本可能成為市場進入的障礙，特別是在醫療保健預算有限的新興國家。此外，新療法的監管障礙和嚴格的審批流程對市場進入造成了障礙，影響了創新和市場成長的步伐。

市場機會：

由於持續的研究和開發、人口變化以及治療模式的新興市場發展，尿失禁治療市場帶來了巨大的商機。藥物配方的創新，例如緩釋配方和聯合治療，可以提高患者的依從性和治療結果。數位醫療技術的整合，包括行動醫療應用和遠距醫療，將改善患者獲得治療和後續護理的機會。此外，策略合作夥伴關係、臨床試驗投資以及開發具有成本效益的治療解決方案對於利用新機會和維持市場成長非常重要。

本報告涵蓋的主要問題

  • 推動全球尿失禁治療市場成長的關鍵因素是什麼？
  • 哪些治療類型和方式引領各種醫療機構採用尿失禁治療？
  • 技術進步如何改變尿失禁治療市場的競爭格局？
  • 誰是尿失禁治療市場的主要參與者？
  • 全球尿失禁治療市場的新趨勢與未來前景如何？

目次

第1章 執行摘要

第2章 市場概要

  • 市場範圍與定義
  • 市場動態
    • 促進要因
    • 抑制要因
    • 機會
    • 課題
    • 主要動向
  • 宏觀經濟因素
    • 世界產業展望
    • 全球 GDP 成長前景
    • 全球醫療支出展望
  • 新冠肺炎（COVID-19）影響分析
  • 預測因子 - 相關性和影響

第3章 附加價值見解

  • 藥物類型採用分析
  • 監理狀況
  • 價值鏈分析
    • 最終用戶/市場列表
      • 零售
      • 聽力學
      • 電子商務
    • 最終用戶（行業）列表
  • 主要交易和合併
  • PESTLE分析
  • 波特五力分析

第4章 尿失禁治療市場展望：実績（2019～2023年）と予測（2024～2031年）

  • 主要亮點
    • 市場規模（十億美元）和年成長率
    • 絕對數量的機會
  • 市場規模分析與預測（十億美元）
    • 過去的市場規模（十億美元）分析，2019-2023年
    • 當前市場規模（十億美元）分析與預測，2024-2031年
  • 尿失禁治療市場前景：類型
    • 簡介/主要調查結果
    • 2019-2023年歷史市場規模（十億美元）分析，依類型
    • 當前市場規模（十億美元）分析與預測，2024-2031年，依類型
      • 急迫性尿失禁
      • 溢流性失禁
      • 壓力性尿失禁
      • 機能性失禁
      • 其他
  • 市場吸引力分析：類型
  • 尿失禁治療市場前景：藥物類別
    • 簡介/主要調查結果
    • 2019-2023年歷史市場規模（十億美元）分析，依藥物類別
    • 2024-2031年當前市場規模（十億美元）的分析和預測，依藥物類別
      • 抗膽鹼能藥物
      • β3 腎上腺素受體促效劑
      • α受體阻斷劑
      • 雌激素
      • 去氨加壓素
      • 三環抗憂鬱藥
      • 其他
  • 市場吸引力分析：藥品類別
  • 尿失禁治療市場前景：最終用戶
    • 簡介/主要調查結果
    • 2019-2023年歷史市場規模（十億美元）分析，依最終用戶
    • 2024-2031目前市場規模（十億美元）的分析與預測，依最終用戶
      • 病院
      • 零售藥局
      • 網路藥局
  • 市場吸引力分析：最終用戶

第5章 尿失禁治療市場展望：地域

  • 2019-2023年過去市場規模（十億美元）分析，依地區
  • 2024-2031年當前市場規模（十億美元）分析和預測，依地區
    • 北美
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東、非洲
  • 市場吸引力分析：地區

第6章 北美尿失禁治療市場展望：實績（2019-2023）與預測（2024-2031）

第7章 歐洲尿失禁治療市場展望：實績（2019-2023年）與預測（2024-2031年）

第8章 東亞尿失禁治療市場展望：實績（2019-2023年）與預測（2024-2031年）

第9章 南亞和大洋洲尿失禁治療市場展望：實績（2019-2023年）和預測（2024-2031年）

第10章 拉丁美洲尿失禁治療市場展望：實績（2019-2023年）與預測（2024-2031年）

第11章 中東和非洲尿失禁治療市場展望：實績（2019-2023年）和預測（2024-2031年）

第12章 競爭情勢

  • 2023年市場佔有率分析
  • 市場構造
    • 依市場劃分的競爭強度圖
    • 競爭儀表板
  • 公司簡介（詳細資料 - 概述、財務狀況、策略、近期發展）
    • Pfizer Inc
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals

第13章 附錄

  • 調查方法
  • 調查假設
  • 首字母縮寫詞和縮寫詞
簡介目錄
Product Code: PMRREP34774

Persistence Market Research has recently released a comprehensive report on the worldwide market for urinary incontinence therapeutics. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

  • Urinary Incontinence Therapeutics Market Size (2024E): US$4.4 Bn
  • Projected Market Value (2031F): US$5.8 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Urinary Incontinence Therapeutics Market - Report Scope:

Urinary incontinence therapeutics encompass a range of treatments designed to manage and alleviate symptoms of urinary incontinence, a condition affecting a substantial portion of the global population. These therapeutics include pharmacological treatments, surgical interventions, and non-pharmacological management strategies. The market caters to hospitals, clinics, urology centers, and homecare settings, offering a variety of therapeutic options, including anticholinergics, beta-3 adrenergic agonists, surgical devices, and pelvic floor muscle training.

Market Growth Drivers:

The global urinary incontinence therapeutics market is driven by several key factors, including the rising prevalence of urinary incontinence among the aging population and increasing awareness about available treatment options. Advances in therapeutic technologies, such as minimally invasive surgical techniques and novel pharmacological agents, are enhancing treatment efficacy and patient satisfaction. Additionally, the growing adoption of lifestyle modifications and behavioral therapies, along with increasing healthcare expenditures, is fueling market expansion.

Market Restraints:

Despite positive growth prospects, the urinary incontinence therapeutics market faces challenges related to high treatment costs, limited insurance coverage, and variability in patient response to different therapies. The high cost of advanced surgical procedures and long-term pharmacological treatments can be a barrier to market accessibility, particularly in emerging economies with constrained healthcare budgets. Moreover, regulatory hurdles and stringent approval processes for new therapeutics contribute to market entry barriers, affecting the pace of innovation and market growth.

Market Opportunities:

The urinary incontinence therapeutics market presents significant opportunities driven by ongoing research and development, demographic shifts, and evolving treatment paradigms. Innovations in drug formulations, such as extended-release and combination therapies, offer improved patient compliance and therapeutic outcomes. The integration of digital health technologies, including mobile health applications and telemedicine, enhances patient access to treatment and follow-up care. Furthermore, strategic partnerships, investment in clinical trials, and the development of cost-effective treatment solutions are crucial to capitalizing on emerging opportunities and sustaining market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urinary incontinence therapeutics market globally?
  • Which therapeutic types and treatment modalities are leading the adoption of urinary incontinence therapies across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the urinary incontinence therapeutics market?
  • Who are the key players contributing to the urinary incontinence therapeutics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global urinary incontinence therapeutics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urinary incontinence therapeutics market, including Pfizer Inc., Astellas Pharma Inc., Allergan plc, and Medtronic plc, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced therapeutic solutions, including novel drug formulations and innovative surgical devices, catering to diverse patient needs and clinical requirements. Partnerships with healthcare providers, regulatory agencies, and research institutions facilitate market access and promote technology adoption. Emphasis on clinical research, patient education, and personalized treatment approaches drives market growth and enhances patient outcomes in the evolving urinary incontinence therapeutics landscape.

Key Companies Profiled:

  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Allergan plc
  • Medtronic plc
  • Boston Scientific Corporation
  • Coloplast A/S
  • Urovant Sciences Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Endo International plc
  • Kaken Pharmaceutical Co., Ltd.

Urinary Incontinence Therapeutics Industry Segmentation

By Type

  • Urge Incontinence
  • Overflow Incontinence
  • Stress Incontinence
  • Functional Incontinence

By Drug Class

  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants

By End User

  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Urinary Incontinence Therapeutics Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Drug Type Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
    • 3.3.1. List of End-user/Marketplaces
      • 3.3.1.1. Retail
      • 3.3.1.2. Audiology
      • 3.3.1.3. E-Commerce
    • 3.3.2. List of End User (Industry)
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
  • 4.3. Urinary Incontinence Therapeutics Market Outlook: Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
      • 4.3.3.1. Urge Incontinence
      • 4.3.3.2. Overflow Incontinence
      • 4.3.3.3. Stress Incontinence
      • 4.3.3.4. Functional Incontinence
      • 4.3.3.5. Other
  • 4.4. Market Attractiveness Analysis: Type
  • 4.5. Urinary Incontinence Therapeutics Market Outlook: Drug Class
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
      • 4.5.3.1. Anticholinergics
      • 4.5.3.2. Beta-3 Adrenoceptor Agonists
      • 4.5.3.3. Alpha Blockers
      • 4.5.3.4. Estrogen
      • 4.5.3.5. Desmopressin
      • 4.5.3.6. Tricyclic Antidepressants
      • 4.5.3.7. Other
  • 4.6. Market Attractiveness Analysis: Drug Class
  • 4.7. Urinary Incontinence Therapeutics Market Outlook: End-user
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
      • 4.7.3.1. Hospitals
      • 4.7.3.2. Retail Pharmacy
      • 4.7.3.3. Online Pharmacy
  • 4.8. Market Attractiveness Analysis: End-user

5. Urinary Incontinence Therapeutics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 6.3.1. By Country
    • 6.3.2. By Type
    • 6.3.3. By Drug Class
    • 6.3.4. By End-user
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 6.4.1. U.S.
    • 6.4.2. Canada
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 6.5.1. Urge Incontinence
    • 6.5.2. Overflow Incontinence
    • 6.5.3. Stress Incontinence
    • 6.5.4. Functional Incontinence
    • 6.5.5. Other
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 6.6.1. Anticholinergics
    • 6.6.2. Beta-3 Adrenoceptor Agonists
    • 6.6.3. Alpha Blockers
    • 6.6.4. Estrogen
    • 6.6.5. Desmopressin
    • 6.6.6. Tricyclic Antidepressants
    • 6.6.7. Other
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 6.7.1. Hospitals
    • 6.7.2. Retail Pharmacy
    • 6.7.3. Online Pharmacy
  • 6.8. Market Attractiveness Analysis

7. Europe Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.3.1. By Country
    • 7.3.2. By Type
    • 7.3.3. By Drug Class
    • 7.3.4. By End-user
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. U.K.
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Russia
    • 7.4.7. Turkey
    • 7.4.8. Rest of Europe
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 7.5.1. Urge Incontinence
    • 7.5.2. Overflow Incontinence
    • 7.5.3. Stress Incontinence
    • 7.5.4. Functional Incontinence
    • 7.5.5. Other
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 7.6.1. Anticholinergics
    • 7.6.2. Beta-3 Adrenoceptor Agonists
    • 7.6.3. Alpha Blockers
    • 7.6.4. Estrogen
    • 7.6.5. Desmopressin
    • 7.6.6. Tricyclic Antidepressants
    • 7.6.7. Other
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 7.7.1. Hospitals
    • 7.7.2. Retail Pharmacy
    • 7.7.3. Online Pharmacy
  • 7.8. Market Attractiveness Analysis

8. East Asia Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.3.1. By Country
    • 8.3.2. By Type
    • 8.3.3. By Drug Class
    • 8.3.4. By End-user
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. South Korea
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 8.5.1. Urge Incontinence
    • 8.5.2. Overflow Incontinence
    • 8.5.3. Stress Incontinence
    • 8.5.4. Functional Incontinence
    • 8.5.5. Other
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 8.6.1. Anticholinergics
    • 8.6.2. Beta-3 Adrenoceptor Agonists
    • 8.6.3. Alpha Blockers
    • 8.6.4. Estrogen
    • 8.6.5. Desmopressin
    • 8.6.6. Tricyclic Antidepressants
    • 8.6.7. Other
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 8.7.1. Hospitals
    • 8.7.2. Retail Pharmacy
    • 8.7.3. Online Pharmacy
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.3.1. By Country
    • 9.3.2. By Type
    • 9.3.3. By Drug Class
    • 9.3.4. By End-user
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.4.1. India
    • 9.4.2. Southeast Asia
    • 9.4.3. ANZ
    • 9.4.4. Rest of South Asia & Oceania
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 9.5.1. Urge Incontinence
    • 9.5.2. Overflow Incontinence
    • 9.5.3. Stress Incontinence
    • 9.5.4. Functional Incontinence
    • 9.5.5. Other
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 9.6.1. Anticholinergics
    • 9.6.2. Beta-3 Adrenoceptor Agonists
    • 9.6.3. Alpha Blockers
    • 9.6.4. Estrogen
    • 9.6.5. Desmopressin
    • 9.6.6. Tricyclic Antidepressants
    • 9.6.7. Other
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 9.7.1. Hospitals
    • 9.7.2. Retail Pharmacy
    • 9.7.3. Online Pharmacy
  • 9.8. Market Attractiveness Analysis

10. Latin America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.3.1. By Country
    • 10.3.2. By Type
    • 10.3.3. By Drug Class
    • 10.3.4. By End-user
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.4.1. Brazil
    • 10.4.2. Mexico
    • 10.4.3. Rest of Latin America
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 10.5.1. Urge Incontinence
    • 10.5.2. Overflow Incontinence
    • 10.5.3. Stress Incontinence
    • 10.5.4. Functional Incontinence
    • 10.5.5. Other
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 10.6.1. Anticholinergics
    • 10.6.2. Beta-3 Adrenoceptor Agonists
    • 10.6.3. Alpha Blockers
    • 10.6.4. Estrogen
    • 10.6.5. Desmopressin
    • 10.6.6. Tricyclic Antidepressants
    • 10.6.7. Other
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 10.7.1. Hospitals
    • 10.7.2. Retail Pharmacy
    • 10.7.3. Online Pharmacy
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Pricing Analysis
  • 11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.3.1. By Country
    • 11.3.2. By Type
    • 11.3.3. By Drug Class
    • 11.3.4. By End-user
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.4.1. GCC Countries
    • 11.4.2. Egypt
    • 11.4.3. South Africa
    • 11.4.4. Northern Africa
    • 11.4.5. Rest of Middle East & Africa
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 11.5.1. Urge Incontinence
    • 11.5.2. Overflow Incontinence
    • 11.5.3. Stress Incontinence
    • 11.5.4. Functional Incontinence
    • 11.5.5. Other
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 11.6.1. Anticholinergics
    • 11.6.2. Beta-3 Adrenoceptor Agonists
    • 11.6.3. Alpha Blockers
    • 11.6.4. Estrogen
    • 11.6.5. Desmopressin
    • 11.6.6. Tricyclic Antidepressants
    • 11.6.7. Other
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 11.7.1. Hospitals
    • 11.7.2. Retail Pharmacy
    • 11.7.3. Online Pharmacy
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer Inc
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Type
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. AbbVie Inc.
    • 12.3.3. Astellas Pharma Inc.
    • 12.3.4. Johnson & Johnson
    • 12.3.5. Viatris Inc.
    • 12.3.6. Teva Pharmaceutical Industries Ltd.
    • 12.3.7. Sanofi S.A.
    • 12.3.8. GlaxoSmithKline plc
    • 12.3.9. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 12.3.10. Bayer AG
    • 12.3.11. Ferring Pharmaceuticals

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations